Sonnet Biotherapeutics Reports Encouraging Data From Phase 1B/2a Clinical Trial of Son-080 in Chemotherapy-Induced Peripheral Neuropathy (Cipn) That Support Advancement Into Phase 2 Study
Sonnet Biotherapeutics報告了Son-080在化療誘導的周圍神經病變（Cipn）Phase 1B/2a臨床試驗中令人鼓舞的數據，支持進入Phase 2研究。